Clinical Roundup Lifileucel + pembrolizumab show promise for advanced melanoma in data from phase II study May 31, 2024Vol.50 No.22
Clinical Roundup Combination therapy improves PFS, OS for metastatic colorectal cancer in phase Ib/II study May 31, 2024Vol.50 No.22
Clinical Roundup Datopotamab deruxtecan did not reach statistical significance for OS in metastatic or advanced nonsquamous NSCLC in phase III trial May 31, 2024Vol.50 No.22
Clinical Roundup ACCC and LUNGevity launch virtual roadmap to support EHR integration for biomarker testing May 31, 2024Vol.50 No.22
Drugs & Targets FDA grants accelerated approval to selpercatinib for pediatric RET-altered metastatic thyroid cancer or solid tumors May 31, 2024Vol.50 No.22
Drugs & Targets FDA acknowledges BLA resubmission for Zolbetuximab for HER2- gastric or GEJ adenocarcinoma with CLDN18.2-positive tumors May 31, 2024Vol.50 No.22
Drugs & Targets European Commission approves Opdivo combination for unresectable or metastatic UC May 31, 2024Vol.50 No.22
Drugs & Targets NHS England will wait to consider NHS rollout of Galleri multi-cancer early detection test May 31, 2024Vol.50 No.22
